50th week of 2011 patent applcation highlights part 31 |
Patent application number | Title | Published |
20110305687 | ANTI-FGFR2 ANTIBODIES - Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2. | 2011-12-15 |
20110305688 | NEW VIRULENCE FACTORS OF STREPTOCOCCUS PNEUMONIAE - The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of | 2011-12-15 |
20110305689 | TREATMENT OF CHRONIC INFLAMMATORY RESPIRATORY DISORDERS - This invention relates, e.g., to a method for treating a subject having a chronic inflammatory respiratory disorder, comprising administering to the subject an effective amount of an inhibitor of the expression of and/or the activity of VEGF-A and/or VEGFR1 and/or VEGFR2 and/or NP1, or a combination thereof. Also described are screeing assays for agents for treating a subject having a chronic inflammatory respiratory disorder, and kits for performing one of the methods of the invention. | 2011-12-15 |
20110305690 | ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND CYCLOPHOSPHAMIDE - Pharmaceutical composition comprising an antibody specifically recognizing CD38 and cyclophosphamide. | 2011-12-15 |
20110305691 | MODIFIED POLYPEPTIDES STABILIZED IN A DESIRED CONFORMATION AND METHODS FOR PRODUCING SAME - The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where crysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. | 2011-12-15 |
20110305692 | ANTIGEN-BINDING CONTRUCTS - The invention relates to combinations of RANKL antagonists with TNF-alpha antagonists and provides antigen-binding constructs which bind to RANKL comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof. | 2011-12-15 |
20110305693 | ANITIGEN-BINDING CONSTRUCTS - The invention relates to combinations of RANKL antagonists with TNF-alpha antagonists and provides antigen-binding constructs which bind to RANKL comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VHNL domain, methods of making such constructs and uses thereof. | 2011-12-15 |
20110305694 | MULTIVALENT AND/OR MULTISPECIFIC RANKL-BINDING CONSTRUCTS - The invention relates to a combination of RANKL antagonists with OSM antagonists, and provides antigen-binding constructs which bind to RANKL comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof | 2011-12-15 |
20110305695 | Wnt Antagonists and Methods of Treatment and Screening - The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use. | 2011-12-15 |
20110305696 | ANTI-SERUM ALBUMIN BINDING VARIANTS - The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts. | 2011-12-15 |
20110305697 | FC FUSION PROTEINS - The invention relates to fusion proteins comprising at least a first domain and a second domain selected from a constant Fc immunoglobulin domain; wherein there is at least one amino acid overlap between the first domain and the second domain in the fusion region. In a preferred embodiment of the invention, the first domain is a ligand-binding receptor domain comprising the extra-cellular domain of a membrane-anchored receptor or a ligand-binding fragment thereof. | 2011-12-15 |
20110305698 | Treating Breast Cancer and Inhibiting Cancer-Associated Bone loss with Anti-IL-20 Antibody - Use of an anti-IL-20 antibody, either alone or in combination with an anti-RANKL antibody, for treating breast cancer and inhibiting cancer-associated bone loss. | 2011-12-15 |
20110305699 | Treating Oral Cancer with Anti-IL-20 Antibody - Treating oral cancer with an anti-IL-20 antibody. | 2011-12-15 |
20110305700 | Anti-lipid antibodies - The present invention relates, in general, to anti-lipid antibodies and, in particular, to methods of inhibiting HIV-1 infection using anti-lipid (e.g. antiphospholipid) antibodies. | 2011-12-15 |
20110305701 | Methods and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases - The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1. In addition, the invention includes methods of diagnosing Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis in a subject. Also, the invention provides methods of identifying substances for the treatment or prevention of Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis and kits using the binding proteins of the invention. | 2011-12-15 |
20110305702 | EPITOPES - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 2011-12-15 |
20110305703 | ISOLATED VEGF-C AND VEGF-D PEPTIDES AND USES THEREOF - The invention relates to an isolated peptide, comprising residues 147 to 151 of SEQ ID NO: 1, or a modification thereof, and antibodies thereto and uses thereof, wherein the peptide comprises 100 or fewer amino acids. | 2011-12-15 |
20110305704 | ANTIBODY TO CYTOLETHAL DISTENDING TOXIN OF CAMPYLOBACTER JEJUNI - Methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering COT inhibitors and/or COT neutralizers to a subject in need thereof are described. Methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS are also provided. Methods of diagnosing IBS by detecting the presence or absence of COT or a COT marker in a subject are described. | 2011-12-15 |
20110305705 | ANTIBODIES TO THYMIC STROMAL LYMPHOPOIETIN RECEPTOR MOLECULES AND USES THEREOF - The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides. | 2011-12-15 |
20110305706 | Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta - The present invention relates to methods for restoring fast axonal transport in a cell affected by oligomeric amyloid beta and for treating an oligomeric amyloid beta-mediated disease such as Alzheimer's disease using a Casein Kinase 2 inhibitor and, in some embodiments, a Glycogen Synthase Kinase 3 inhibitor. | 2011-12-15 |
20110305707 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention provides methods for treating cancer in a subject, as well as related compositions and kits that employ a therapeutic agent, or a nucleic acid sequence encoding a therapeutic agent, selected from apolipoprotein A-1 (ApoA1) or biologically active fragment, an ApoA1 mimetic, an agent that increases expression of ApoA1, or a binding agent specific for oxidized ApoA1. In certain embodiments, the ApoA1 or ApoA1 mimetic is at least partially oxidation resistant. | 2011-12-15 |
20110305708 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CYTOMEGALOVIRUS - The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection. | 2011-12-15 |
20110305709 | CALCIUM SENSOR STIM1 AND THE PLATELET SOC CHANNEL ORAI1 (CRACM1) ARE ESSENTIAL FOR PATHOLOGICAL THROMBUS FORMATION - The present invention relates to a pharmaceutical composition comprising an inhibitor of stromal interaction molecule 1 (STIM1) or an inhibitor of STIM1-regulated plasma membrane calcium channel activity, in particular an inhibitor of Orai1 (also designated as CRACM1), and optionally a pharmaceutically active carrier, excipient or diluent. The invention further relates to an inhibitor of stromal interaction molecule 1 (STIM1) or an inhibitor of STIM1-regulated plasma membrane calcium channel activity, in particular an inhibitor of Orai | 2011-12-15 |
20110305710 | NOVEL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION - This invention relates to compositions and methods for the treatment or prophylaxis of glaucoma and ocular hypertension, and for lowering of intraocular pressure. The invention provide VEGFR-1 agonists and combinations of vascular endothelial growth factor B (VEGF-B) with placenta growth factor (PLGF), ‘ Secreted protein acidic cysteine-rich’ (SPARC) antagonists, insulin, insulin like growth factor, their isoforms, their analoges, their gene-engineered modifications. Furthermore, the formentioned compositions and combinations are provided for coadministration with antiglaucoma agents, currently in clinical use, for the treatment or prophylaxis of glaucoma and ocular hypertension, for lowering of intraocular pressure, for increasing success rate of surgical procedures for the treatment or prophylaxis of glaucoma, and for preserving retinal ganglion cells. | 2011-12-15 |
20110305711 | CGRP ANTIBODIES - The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain. | 2011-12-15 |
20110305712 | CTLA4 PROTEINS AND THEIR USES - The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses. | 2011-12-15 |
20110305713 | METHODS AND COMPOSITIONS TO ENHANCE VACCINE EFFICACY BY REPROGRAMMING REGULATORY T CELLS - The immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by a subset of murine plasmacytoid DCs (pDCs) in tumor-draining LNs, where it can potently activate Foxp3 regulatory T cells (Tregs). We now show that IDO functions as a molecular switch in tumor-draining LNs, maintaining Tregs in their normal suppressive phenotype when IDO was active, but allowing inflammation-induced conversion of Tregs to a polyfunctional T-helper phenotype similar to proinflammatory TH17 cells when IDO was blocked. In vitro, conversion of Tregs to the TH17-like phenotype was driven by antigen-activated effector T cells, and required IL-6 produced by activated pDCs. IDO regulated this conversion by dominantly suppressing production of IL-6 in pDCs, in a GCN2-kinase dependent fashion. In vivo, using a model of established B16 melanoma, the combination of an IDO-inhibitor drug plus anti-tumor vaccine caused upregulation of IL-6 in pDCs and in situ conversion of a majority of Tregs to the TH17 phenotype, with marked enhancement of CD8 | 2011-12-15 |
20110305714 | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same - The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC. | 2011-12-15 |
20110305715 | ANTIBODIES TO 3-HYDROXYCOTININE AND METHODS OF USE THEREOF - The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to 3-hydroxycotinine (3HC). The invention also provides compositions containing these antibodies and fragments thereof, and to their use in diagnostic and therapeutic applications for diseases involving nicotine activity (e.g., smoking and/or smokeless tobacco use). | 2011-12-15 |
20110305716 | TARGETED CYTOKINE FOR TREATMENT OF DISEASES - Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided proteins and complexes are complexes containing a TGF-beta associated with immunoglobulins (such as IgGs) or functional portions thereof including Fc portions, such as by non-covalent bonds. The provided complexes include those in which the immunoglobulin portion binds to inhibitory Fcγ receptors to a greater degree than to activating Fcγ receptors. The provided complexes further include those in which the immunoglobulin portion bind to activating Fcγ receptors to a greater degree than to inhibitory Fcγ receptors. The complexes and compositions can be used for administration to subjects, such as for increasing immunity or decreasing inflammation, such as for treating diseases including autoimmune diseases and cancer. | 2011-12-15 |
20110305717 | CULTURED MYELOID DENDRITIC CELLS ISOLATED FROM PEYER'S PATCHES AND USES THEREOF - Cultured lysozyme-secreting myeloid dendritic cells isolated from the subepithelial dome of Peyer's patches in the small intestine are provided. The myeloid dendritic cells are used in screening methods to identify agents which interact with myeloid dendritic cells, for example, antigens, allergens, antimicrobial agents, or agents that modulate the activity of myeloid dendritic cells. The cells are also used to identify agents which bind to and/or are taken up by myeloid dendritic cells, and which can act as delivery vehicles for delivering substances of interest to myeloid dendritic cells in vivo. | 2011-12-15 |
20110305718 | Recombinant Protein Body-Inducing Polypeptides - Polypeptide sequences for inducing recombinant protein bodies are described. The sequences comprise a polyproline II (PPII) structure and/or a proline-rich sequence between two cysteine residues on either end. Recombinant protein bodies are useful for protein production because they allow for simple and efficient purification of high quantities of recombinant protein. In addition, other methods of using recombinant protein bodies, for example, in vaccination and food products, are also described. | 2011-12-15 |
20110305719 | Inhibition of Pro-Inflammatory Cytokine Induced Response - Method and compositions for reducing the inflammation after cytokine exposure of an islet cell transplant without affecting the viability and potency are disclosed herein. The present invention describes a composition comprising Withaferin A (WA), a steroidal lactone derived from | 2011-12-15 |
20110305720 | PEPTIDE ADJUVANTS - Adjuvant compositions comprising specific 5 mer polypeptides in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described. | 2011-12-15 |
20110305721 | COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS - Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more | 2011-12-15 |
20110305722 | MAGE-C2 ANTIGENIC PEPTIDES AND USES THEREOF - This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ∃ | 2011-12-15 |
20110305723 | Molecular Antigen Array - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses. | 2011-12-15 |
20110305724 | IMMUNOTHERAPEUTIC, ANTI-TUMORIGENIC COMPOSITIONS AND METHODS OF USE THEREOF - This invention relates to immunotherapeutic vaccine composition comprising an ISG15 tumor antigen and to methods of preventing and treating a tumor growth by using said immunotherapeutic composition. | 2011-12-15 |
20110305725 | METHODS AND COMPOSITIONS FOR IMMUNIZING PIGS AGAINST PORCINE CIRCOVIRUS - The present invention relates to the isolation and identification of two new strains of type 2B porcine circovirus. These two new strains of porcine circovirus may be used for the preparation of vaccine or immunogenic compositions for immunizing pigs against postweaning multisystemic wasting syndrome (PMWS). Accordingly, the invention provides methods for eliciting a protective immune response against a pathogenic porcine circovirus by administering to a pig an immunogenically effective amount of a type 2B porcine circovirus vaccine or immunogenic composition comprising at least one of the porcine circoviruses having a nucleic acid sequence as set forth in SEQ ID NOs: 1 or 2, or at least one protein from at least one of the two new type 2B strains of porcine circovirus as described herein. The invention further relates to protection of a pig from any one or more of the symptoms or sequelae associated with PMWS. | 2011-12-15 |
20110305726 | Infectious Bronchitis Vaccines Derived From IB-qx-like Vaccine Strains - The present invention relates to infectious bronchitis (IB) viruses derived from a recently identified genotype of IB virus known as IB-QX, or from viruses that are genetically related to IB-QX, herein referred to as IB-QX-like viruses. The IB viruses of the invention may be live and attenuated or inactivated. Live, attenuated IB viruses of the invention may be produced by serial passaging of an IB-QX-like virus. The IB viruses of the invention are useful for, inter alia, vaccines against IB-QX and IB-QX-like viruses. Heretofore, known vaccine strains of IB viruses have proven insufficient to protect against infectious bronchitis caused by IB-QX and IB-QX-like viruses. | 2011-12-15 |
20110305727 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME - The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F. | 2011-12-15 |
20110305728 | DRUG FOR TREATING INFECTIONS - The invention relates to the use of glycoproteins extracted from the | 2011-12-15 |
20110305729 | Scriptaid Isosteres and Their Use in Therapy - Compounds of the invention are of the formula (I); wherein: | 2011-12-15 |
20110305730 | MONO-AND DISACCHARIDE DERIVATIVES - The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for, inter alia, medical, pharmaceutical, cosmetic and food applications. | 2011-12-15 |
20110305731 | PHARMACEUTICAL FORMULATION BETWEEN JASMONATES AND IT DERIVATIVES AND NANOCARRIES OR MICROCARRIES - The present invention refers to pharmaceutical compositions comprising a jasmonic acid derivative and a carrier, preferably cyclodextrin or a polyamidoamine. The compositions may be used for treating cancer. | 2011-12-15 |
20110305732 | METHODS AND USES FOR INHIBITING PLATELET COAGULATION - The present disclosure provides methods and uses of Slit proteins and nucleic acids for inhibiting platelet coagulation and related disorders. Further provided is a vascular device coated with Slit protein or a cell expressing a Slit protein. | 2011-12-15 |
20110305733 | PHARMACEUTICAL FORMULATIONS COMPRISING METFORMIN AND A FIBRATE, AND PROCESSES FOR OBTAINING THEM - The present invention relates to granulates comprising particles of metformin and particles of a fibrate. The invention further relates to pharmaceutical compositions containing such granulates. The invention also relates to processes for preparing said granulates and said pharmaceutical compositions. | 2011-12-15 |
20110305734 | NUCLEIC ACID NANOPARTICLES AND USES THEREFOR - The present invention provides nanoparticle compositions including one or more nucleic acids. The present invention achieves delivery (particularly transdermal delivery) of such nucleic acids without the need for nucleic acid modification, or for use of chemical or mechanical abrasion or disruption of skin. | 2011-12-15 |
20110305735 | SKIN ANTIAGING TREATMENT - A method for skin antiaging treatment comprising administering Botulinum toxin to an area of facial and/or neck skin, combined with the administration of a cosmetic or pharmaceutical composition comprising a cosmetically or pharmaceutically effective amount of at least one peptide derived from the SNAP-25 protein and/or at least one enkephalin-derived peptide, and at least one cosmetically or pharmaceutically acceptable excipient or adjuvant. | 2011-12-15 |
20110305736 | Stratiform Perforated Biomatrices - The present invention relates to stratiform biomatrices that are formed from regularly shaped, uniformly arranged portions which are connected to one another by continuous, straight-through perforations, and also to the use thereof as cosmetic or pharmaceutical agents, such as, in particular, as agents for wound treatment. The present invention further relates to a process for producing stratiform biomatrices of such a type, and also to the combination thereof in kit-of-parts arrangements. | 2011-12-15 |
20110305737 | Multi-Active Microtargeted Anti-Aging Skin Cream Polymer Technology - A comprehensive, single agent cosmetic cream or lotion containing a high number of ingredients that target anti-aging in a defined manner. The cream or lotion contains a high number and variety of active substances that demonstrate excellent safety and efficacy in all of the various defined categories of skin aging, including but not limited to wrinkles, abnormal pigment or brown spots due to aging of the skin and an unexpectedly high efficacy in the reduction of redness and acne and rosacea blemishes. | 2011-12-15 |
20110305738 | Oxygenating Oral Compositions - Oral compositions, which are preferably chewable compositions, containing a peroxide source and a peroxide decomposition catalyst in a contactless manner liberate molecular oxygen in the oral cavity upon use by catalyzed decomposition of the peroxide source. The oral composition promotes oral health by providing a more aerobic environment for oral flora. | 2011-12-15 |
20110305739 | Method for Preparing a Non-Ionic Surfactant Stable Personal Care Dispersion - Disclosed herein are methods for preparing dispersions containing small diameter, liquid crystals of a high charge density cationic polymer and a detersive surfactant. Also disclosed herein are uses of these dispersions to prepare personal care products and liquid cleansing products. | 2011-12-15 |
20110305740 | GRANULATED POWDER CONTAINING VEGETABLE PROTEINS AND MALTODEXTRINS, PROCESS FOR PRODUCING SAME, AND USES THEREOF - The present invention concerns a granulated powder comprising at least one vegetable protein and at least one starch hydrolyzate, characterized in that it has a laser volume average diameter D4,3 of between 10 μm and 500 μm, preferably between 50 μm and 350 μm, and even more preferably between 70 μm and 250 μm, and a dry matter content, determined after stoving at 130° C. for 2 hours, of greater than 80%, preferably greater than 85%, and even more preferably greater than 90%. | 2011-12-15 |
20110305741 | Composition and Method for Delivery of BMP-2 Amplifier/Co-Activator for Enhancement of Osteogenesis - A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction. | 2011-12-15 |
20110305742 | PHARMACEUTICAL COMPOSITIONS - A device implantable into a human or animal body comprising a biodegradable polymer which comprises ethylene carbonate units of the formula A | 2011-12-15 |
20110305743 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS - The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release. | 2011-12-15 |
20110305744 | PREPARATION FOR VAGINAL AND RECTAL USE AND RELATIVE PRODUCTION METHOD - A preparation for vaginal and rectal use comprising hyaluronic acid, with an average particle size comprised between about 50 micrometers and about 200 micrometers and a molecular weight comprised between about 1,000,000 Da and about 1,800,000 Da. | 2011-12-15 |
20110305745 | Pollulan regenerative matrix - Compositions and methods are provided for the manufacture and use of a pullulan-based collagen hydrogel film with controlled porosity. The hydrogel is fabricated with salt-induced phase inversion and cross-linking to form a reticular scaffold. This soft collagen scaffold displays excellent handling characteristics, durability, and a porous dermal-like ultrastructure that is maintained in vitro. Cells, including cells involved in tissue repair, are viably sustained within the scaffold. The hydrogel films are biodegradable, and find particular use in wound healing, where the hydrogel scaffold can be replaced by dermal cells over time. | 2011-12-15 |
20110305746 | PATCH FOR TREATING CONSTIPATION USING CRUDE DRUGS - The present invention relates to a patch for treating constipation, which contains rhubarb ingredients selected from among crude drugs (medical herbs). More particularly, the present invention relates to a patch for treating constipation in which powder obtained by boiling, filtering, and free-drying rhubarb selected from among pure crude drugs is applied to the patch, and the patch is attached to the recesses (arched parts) below the wrists of both hands of a patient, to thereby increase the metabolism of internal organs of the patient and exhibit the effects of treating or preventing constipation. The patch of the present invention can be simply attached to the skin of the patient instead of directly administering agents for treating constipation to the patient. | 2011-12-15 |
20110305747 | COMBINATION OF DAPSONE WITH OTHER ANTI-ACNE AGENTS - A composition suitable for topical application that contains at least two active ingredients, one of these being dapsone and one selected from the group consisting of adapalene, tazarotene and treinion for the effective treatment of acne and other dermatological conditions. | 2011-12-15 |
20110305748 | Vaccines for Pandemic Influenza - Pharmaceutical and vaccine compositions comprise recombinant hemagglutinin from a pre-pandemic or pandemic influenza virus and an adjuvant comprising GLA. A particularly relevant pre-pandemic influenza virus is H5N1. Kits and methods of using the compositions are also provided. | 2011-12-15 |
20110305749 | HIV-1 Envelope Polypeptides for HIV Vaccine - Immunogenic HIV-1 envelope polypeptides are provided, wherein specific amino acid residues are mutated to repress immunosuppression in GP41, thereby boosting the immune response against HIV-1. Specifically, mutation of those specific residues does not affect the fusogenic properties of the viral particle and/or the overall protein structure of the viral envelope protein. The invention further provides peptides and antigens based on the immunogenic HIV-1 envelopes as well as nucleic acid sequences and vectors encoding those. Moreover, biological entities such as viral particles are provided, as well as use of the provided components for preparation of a vaccine against HIV-1/AIDS. | 2011-12-15 |
20110305750 | MEMBRANE TYPE-1 MATRIX METALLOPROTEIN INHIBITORS AND USES THEREOF - Based on the discovery that a soluble polypeptide including a nonphosphorylatable form of the cytoplasmic domain is capable of inhibiting in a dominant negative manner, the present invention provides compositions including MT1-MMP inhibitors such as peptide inhibitors, and methods for treating diseases associated with MT1-MMP activity. Such diseases include cancer, arthritis, and heart disease, and vascular disease. | 2011-12-15 |
20110305751 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM - The invention relates to methods of targeted drug delivery of compounds, including, chemical agents, (poly)peptides and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of compounds to extravascular and intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to glutathione transporters present on these cells, tissues and organs. Thereto, the compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to glutathione-based ligands that facilitate the specific binding to and internalization by these glutathione transporters. | 2011-12-15 |
20110305752 | LIPOSOME-ENCAPSULATED GLUTATHIONE FOR ORAL ADMINISTRATION - The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa. | 2011-12-15 |
20110305753 | Treatment of celiac disease with IgA - A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an IgA or an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgA or IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgA and IgM are effective when administered orally. | 2011-12-15 |
20110305754 | CONTROLLED RELEASE MICRO-CAPSULE FOR OSTEOGENIC ACTION - The present invention relates to a microcapsule for controlled release of flavanoid compound and a process for preparation thereof. The microcapsule comprising a core particle consisting of a calcium salt, Pluronic F68 [poly (ethylene oxide-co-polypropylene co-polypropylene oxide), block poly oxyethylene-polypropylene block copolymer], loaded with a flavanoid compound, the resulting core particle having a plurality of alternate layers of cationic and anionic polyelectrolytes adsorbed thereon and an outer layer formed by a bile salt, wherein the flavanoid is ranging between 10 to 96% by weight. | 2011-12-15 |
20110305755 | METHOD OF ADDING BOTANICAL AGENTS/DIETARY SUPPLEMENTS TO PHARMACEUTICAL AGENTS IN A PHARMACOTHERAPEUTIC REGIMEN - A method for administering an active pharmaceutical agent (APA) is provided that includes the steps of: a) providing a medicine having a dose of at least one APA and at least one active botanical agent (ABA) or dietary supplement; and b) dosing the APA within the medicine such that within each subsequent dose of the medicine, the amount of the APA decreases and the amount of the ABA increases, or remains the same, or decreases relative to an earlier amount. A trace of the APA may or may not remain in the pill toward the end of medicine application. | 2011-12-15 |
20110305756 | COATED SOLID PREPARATION - A coated solid preparation includes an active ingredient including valproic acid or a pharmacologically acceptable salt thereof, and a coating layer containing polyvinyl alcohol and swelling clay coating the active ingredient wherein mass ratio of the polyvinyl alcohol to the swelling clay is 8:2 to 3:7 and the swelling clay is dispersed as a laminated structure. | 2011-12-15 |
20110305757 | NEW PHARMACEUTICAL COMBINATIONS - A pharmaceutical composition including a compound of Formula I (Compound I) or pharmaceutically acceptable salts thereof and one or more diuretics as effective components, wherein said one or more diuretics are selected from thiazide derivatives. Methods for preparing the pharmaceutical compound including Compound I and thiazide derivatives and its use for preventing or treating hypertension in mammals, particularly in humans. | 2011-12-15 |
20110305758 | ORALLY DISINTEGRATING TABLET HAVING INNER CORE - The present invention provides an orally disintegrating tablet with improved photostability of a medicament unstable to light. The orally disintegrating tablet has an inner core and an outer layer that covers the surface of the inner core, wherein the inner core contains the medicament unstable to light and the outer layer contains a light-absorbing substance such as Red No. 2, Red No. 3, Yellow No. 4, Yellow No. 5, Blue No. 1, Red No. 3 aluminum lake, Yellow No. 4 aluminum lake, Yellow No. 5 aluminum lake, Blue No. 1 aluminum lake, Blue No. 2 aluminum lake, red ferric oxide, yellow ferric oxide, black iron oxide, carmine, or sodium copper chlorophyllin. | 2011-12-15 |
20110305759 | COMPOSITION COMPRISING CALCIUM CARBONATE AS A WHITE PIGMENT - A white colouring composition comprising calcium carbonate as a white pigment. It may be used in the manufacture of food and pharmaceutical products. | 2011-12-15 |
20110305760 | TISSUE REGENERATION SYSTEM - A system for growing tissue based upon layers of an inorganic extracellular matrix, wherein each layer of the inorganic matrix is designed to dissolve at a separate rate and result in sequential growth factor delivery upon its dissolution. | 2011-12-15 |
20110305761 | POLYMERSOMES, COLLOIDOSOMES, LIPOSOMES, AND OTHER SPECIES ASSOCIATED WITH FLUIDIC DROPLETS - The present invention relates generally to vesicles such as liposomes, colloidosomes, and polymersomes, as well as techniques for making and using such vesicles. In some cases, the vesicles may be at least partially biocompatible and/or biodegradable. The vesicles may be formed, according to one aspect, by forming a multiple emulsion comprising a first droplet surrounded by a second droplet, which in turn is surrounded by a third fluid, where the second droplet comprises lipids and/or polymers, and removing fluid from the second droplet, e.g., through evaporation or diffusion, until a vesicle is formed. In certain aspects, the size of the vesicle may be controlled, e.g., through osmolarity, and in certain embodiments, the vesicle may be ruptured through a change in osmolarity. In some cases, the vesicle may contain other species, such as fluorescent molecules, microparticles, pharmaceutical agents, etc., which may be released upon rupture. Yet other aspects of the invention are generally directed to methods of making such vesicles, kits involving such vesicles, or the like. | 2011-12-15 |
20110305762 | PHARMACEUTICAL COMPOSITION COMPRISING N-[3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-6-[5[[[2-(METHYLSULFONYL)E- THYL]AMINO]METHYL]-2-FURYL]-4- QUINAZOLINAMINE - The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine as active pharmaceutical ingredient and a process of preparing such composition. | 2011-12-15 |
20110305763 | LANTIBIOTICS AND USES THEREOF - The present invention provides isolated lantibiotics that inhibit. Gram negative and Gram positive microbes. The antibiotic includes an amino acid sequence, wherein the amino acid sequence of the compound and the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 have at least 80% identity. The lantibiotics have the characteristic of inhibiting growth of a Gram negative microbe in conditions that do not damage the outer membrane of the Gram negative microbe. The present invention also provides methods for making and using the lantibiotics. | 2011-12-15 |
20110305764 | Use of a Mare's Milk Concentrate Dried on a Highly-Dispersed, Biologically Inert Matrix - The invention relates to the use of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix, for producing a preparation for the treatment of skin diseases, especially dry skin diseases. | 2011-12-15 |
20110305765 | PREPARATION AND METHODOLOGY OF SILK FIBROIN NANOPARTICLES - Disclosed are nanoparticles for delivery of drugs and/or nutraceuticals that include a fibroin polypeptide and a drug or nutraceutical, wherein the nanoparticle has a diameter of about 1 nm to about 500 nm, and compositions of the nanoparticles. The nanoparticles may further include a chitosan, or a proteoglycan such as decorin. Also disclosed are methods of delivering a drug and/or nutraceutical to a subject that involve administering to the subject nanoparticles of the present invention. Also disclosed are methods of making the nanoparticles of the invention, and kits that include the nanoparticles of the invention. | 2011-12-15 |
20110305766 | Method for Controlled Release of Parathyroid Hormone from Encapsulated Poly(Lactic-Glycolic)Acid Microspheres - The present invention provides a method for producing a controlled release microsphere with mean average size greater than 50 μm, comprising preparing a water-in-oil (w/o) emulsion comprising an inner aqueous layer containing a pharmaceutically effective amount of a biologically active polypeptide with activity similar to parathyroid hormone, and an oil layer containing a polymer substance of poly (lactic-co-glycolic acid) (PLGA), then adding the w/o emulsion into aqueous polyvinyl alcohol (PVA) solution to form a water-in-oil-in-water (w/o/w) double emulsion and then desorbing the solvent in the oil layer. The present invention also provides a controlled release microsphere prepared by the method and use thereof. | 2011-12-15 |
20110305767 | Polymer Particles Prepared From Polymerisable Alkylene Glycol (Meth) Acrylate Monomers - The invention provides polymer particles that are obtainable by a method selected from emulsion methods, diffusion methods and evaporation methods carried out in the presence of surface-engineering surfactant which is one or more polymer that displays a lower critical solution temperature, in aqueous media, that is between 10 to 90° C., this polymer being the polymerisation product of one or more monomer selected from polymerisable alkyleneglycol acrylate monomers and polymerisable alkyleneglycol methacrylate monomers. The polymer particles can be used in controlled release applications, such as flavour release applications, fragrance release applications and biomedical applications. The invention also provides a cell support matrix comprising the polymer particles. | 2011-12-15 |
20110305768 | QUICK-DISSOLVING ORAL THIN FILM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS - This invention describes a quick-dissolving thin film strips comprising bioactive components encapsulated within pH-sensitive polymeric microparticles. The microparticles are embedded within the thin film and provide protection to components encapsulated within. The invention further describes methods to incorporate bioactive components encapsulated within pH-sensitive polymeric microparticles into a quick-dissolving thin film strip while maintaining the bioactivity of the contained therapeutic agents during thin film formation and microencapsulation. | 2011-12-15 |
20110305769 | BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM - The present invention is directed to cationic lipid for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to cholesterol and its derivatives having multiple positively charged moieties via branching spacers, and nanoparticle compositions of oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid and a PEG lipid. | 2011-12-15 |
20110305770 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM - The present invention relates to polymer conjugated releasable lipids and nanoparticle compositions containing the same for the delivery of nucleic acids and methods of modulating gene expression using the same. In particular, this invention relates to releasable polymeric lipids containing an acid-labile linker based on a ketal or acetal-containing linker, or an imine-containing linker. | 2011-12-15 |
20110305771 | Krill Extracts for Treatment of Cardiovascular Diseases - The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient. The present invention also relates to a composition for the treatment and/or prevention of these diseases. | 2011-12-15 |
20110305772 | COMPOSITIONS AND METHODS FOR EX VIVO HEPATIC NUCLEIC ACID DELIVERY - The invention provides compositions and methods for delivery of nucleic acids to the liver ex vivo. The method includes slow, low pressure infusion of the nucleic acid into the liver to efficiently transduce cells with minimal cell damage. | 2011-12-15 |
20110305773 | APPROACH TO THE TREATMENT OF COMPARTMENT SYNDROME - The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof. | 2011-12-15 |
20110305774 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS - Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries. | 2011-12-15 |
20110305775 | Micronutrient Supplement Dispensing Package - Provided herein is a prenatal and postpartum multivitamin and mineral supplement package provided in the form of a plurality of solid oral dosage units individually contained in blister packs wherein a portion of the dosage forms are iron-containing while at least half of the dosage units are essentially iron-free and wherein the total amount of iron in the package as sold to purchasers is less than about 1300 mg of elemental iron. | 2011-12-15 |
20110305776 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS - The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). | 2011-12-15 |
20110305777 | DIMERIC IAP ANTAGONISTS - Smac mimetics that inhibit IAPs. | 2011-12-15 |
20110305778 | Chemically Stabilized Anti-Dandruff Compositions For Use In Personal Care Compositions - The present invention is directed to a stabilized anti-dandruff composition comprising about 10 wt. % to about 40 wt. % of an insoluble anti-dandruff agent, about 6 wt. % to about 12 wt. % of a stabilizer, less than about 1 wt. % of a preservative, and about 0.5 wt. % to about 1 wt. % of a neutralizer, and water. In an embodiment of the present invention, it is directed to a stabilized anti-dandruff composition comprising about 10 wt. % to about 25 wt. % of a zinc-containing layered material, about 6 wt. % to about 12 wt. % of a stabilizer, less than about 1 wt. % of a preservative, and about 0.5 wt. % to about 1 wt. % of a neutralizer, and water. | 2011-12-15 |
20110305779 | PHYTOCHEMICAL COMBINATIONS THAT REGULATE PATHOLOGICAL IMMUNITY - Disclosed are dietary supplements comprising a combination of a spice, a partially purified phytochemical, and a fully purified phytochemical that synergistically downregulates inflammation and promotes wellness, good health, and fitness in a mammal. Methods of identifying and making such supplements are likewise provided. The method of identifying comprises contacting mammalian cells, in vitro or in vivo, with the combination, assaying to detect a change in the level of a biomarker that is correlated with downregulation of an inflammatory response of the cells, and identifying a phytochemical composition comprising a combination of spices that synergistically changes the level of the biomarker. Exemplary supplements include a combination of spices selected from (a) turmeric and ginger, (b) turmeric and | 2011-12-15 |
20110305780 | Marrubiin and composition for reducing snoring, package and method - The invention comprises a composition for the reduction of snoring, a packaging therefor and a method for the manufacture thereof. The composition can be applied in the pharynx in different variants, in particular as spray, as gel or as foam formulation. Application of the composition at least temporarily reduces the snoring of a treated person. The invention further comprises the use of marrubiin for the manufacture of a medication for the treatment of snoring. | 2011-12-15 |
20110305781 | Use of Eclipta Prostrata and Other PPAR-GAMMA Inhibitors in Cosmetics and Compositions Thereof - The present invention describes compositions and methods for improving the appearance of skin, particularly, treating, ameliorating, preventing, delaying, and/or improving one or more signs of excess accumulation and/or production of subcutaneous fat, such as cellulite, and conditions related thereto, by topically applying compositions comprising | 2011-12-15 |
20110305782 | METHODS OF CHOLESTEROL REDUCTION USING ISOFLAVONES - This invention relates to natural products containing phyto-oestrogens, or phyto-oestrogen analogues, which have various beneficial physiological effects in man, and which have a variety of uses, such as to promote good health and as a dietary additive, for example. The invention describes a method of improving the health of a human by administering to the human a health supplementing amount of a phyto-oestrogen selected from genistein, daidzein formononentin and/or biochanin A. A health supplement comprising a health supplementary amount of a phyto-oestrogen selected from genisten daidzein formononentin and/or biochanin A, is also described. Preferably, the supplement also comprises at least one dietary suitable excipient, diluent, carrier or food, and may be in the form of a tablet or capsule, for example. Ideally, the phyto-oestrogen is extracted from red clover or from soya, although any source rich in isoflavones may also be used. The supplement can be used to prevent or ameliorate such conditions as breast cancer, benign breast disease, pre-menstrual syndrome, or symptoms associated with menopause in women, or various types of cancer, and especially for high blood cholesterol levels in all humans, for instance. | 2011-12-15 |
20110305783 | Method and pharmaceutical composition for treating psoriasis, squamous cell carcinoma and/or parakeratosis by inhibiting expression of squamous cell carcinoma-related antigen - In a first aspect thereof, the present invention provides a method for treatment and/or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a method for screening for substances that inhibit epidermal parakeratosis, wherein the activity of a candidate substance that inhibits cysteine protease inhibitory activity possessed by squamous cell carcinoma antigen 1 (SCCA-1) is used as an indicator. | 2011-12-15 |
20110305784 | Fractionated products obtained from gamboge resin, and medical uses of the same - Disclosed herein are seventeen new compounds and five fractionated products obtained from an acetone-extracted product of gamboge resin. The seventeen new compounds and the five fractionated products have activities in inhibiting the growth of tumor/cancer cells. In addition, the acetone-extracted product of gamboge resin and the five fractionated products obtained therefrom have analgesic and anti-inflammatory effects. | 2011-12-15 |
20110305785 | BULBINE FRUTESCENS EXTRACT - A method of producing a | 2011-12-15 |
20110305786 | MOLDED ARTICLE TRANSFER DEVICE - A molded article transfer device ( | 2011-12-15 |